Federal Register / Vol. 77, No. 47 / Friday, March 9, 2012 / Notices 14405 

docket number found in brackets in the 

heading of this document. Received 

comments may be seen in the Division 

of Dockets Management between 9 a.m. 

and 4 p.m., Monday through Friday. 

III. Electronic Access 

Persons with access to the Internet 

may obtain the document at http:// 

www.fda.gov/AdvisoryCommittees/ 

default.htm. 

Dated: February 28, 2012. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2012–5776 Filed 3–8–12; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2012–N–0001] 

Preparation for International 

Cooperation on Cosmetics 

Regulations; Public Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of meeting. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing a 

public meeting entitled ‘‘International 

Cooperation on Cosmetics Regulations 

(ICCR)–Preparation for ICCR–6 Meeting 

in Rockville, Maryland’’ to provide 

information and receive comments on 

the International Cooperation on 

Cosmetics Regulations (ICCR) as well as 

the upcoming meetings in Rockville, 

MD. The topics to be discussed are the 

topics for discussion at the forthcoming 

ICCR Steering Committee meeting. The 

purpose of the meeting is to solicit 

public input prior to the next steering 

committee and expert working group 

meetings in Rockville, MD on July10 to 

13, 2012. 

Date and Time: The meeting will be 

held on May 15, 2012, from 2 to 4 p.m. 

Location: The meeting will be held in 

the Washington Theater Room at the 

Hilton Washington DC/Rockville Hotel 

& Executive Meeting Center, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: All participants must 

register with Kimberly Franklin, Office 

of the Commissioner, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Silver Spring, MD 20993, by 

email: Kimberly.Franklin@fda.hhs.gov 

or FAX: 301–595–7937. 

Registration and Requests for Oral 

Presentations: Send registration 

information (including: Name, title, firm 

name, address, telephone, and fax 

number), written material and requests 

to make oral presentation, to the contact 

person by May 9, 2012. 

If you need special accommodations 

due to a disability, please contact 

Kimberly Franklin (see Contact Person) 

at least 7 days in advance. 

Interested persons may present data, 

information, or views orally or in 

writing, on issues pending at the public 

meeting. Time allotted for oral 

presentations may be limited to 10 

minutes. Those desiring to make oral 

presentations should notify the contact 

person by May 9, 2012, and submit a 

brief statement of the general nature of 

the evidence or arguments they wish to 

present, the names and addresses, 

telephone number, FAX and email of 

the proposed participants, and an 

indication of the approximate time 

requested to make their presentation. 

Transcripts: Please be advised that as 

soon as a transcript is available, it will 

be accessible at http:// 

www.regulations.gov. It may be viewed 

at the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD. A transcript will 

also be available in either hardcopy or 

on CD–ROM, after submission of a 

Freedom of Information request. Written 

requests are to be sent to Division of 

Freedom of Information (ELEM–1029), 

Food and Drug Administration, 12420 

Parklawn Dr., Element Bldg. Rockville, 

MD 20857. 

SUPPLEMENTARY INFORMATION: The 

purpose of the multilateral framework 

on the ICCR is to pave the way for the 

removal of regulatory obstacles to 

international trade while maintaining 

global consumer protection. 

ICCR is a voluntary international 

group of cosmetics regulatory 

authorities from the: United States, 

Japan, the European Union, and Canada. 

These regulatory authority members 

will enter into constructive dialogue 

with their relevant cosmetics’ industry 

trade associations. Currently, the ICCR 

members are: Health Canada; the 

European Directorate General for 

Enterprise and Industry; the Ministry of 

Health, Labor and Welfare of Japan; and 

the U.S. Food and Drug Administration. 

All decisions made by consensus will be 

compatible with the laws, policies, 

rules, regulations, and directives of the 

respective administrations and 

governments. Members will implement 

and/or promote actions or documents 

within their own jurisdictions and seek 

convergence of regulatory policies and 

practices. Successful implementation 

will require input from stakeholders. 

Interested persons may present data, 

information, or views orally or in 

writing, on issues pending at the public 

meeting. Time allotted for oral 

presentations may be limited to 10 

minutes. Those desiring to make oral 

presentations should notify the contact 

person by April 22, 2011, and submit a 

brief statement of the general nature of 

the evidence or arguments they wish to 

present, the names and addresses, 

telephone number, fax, and email of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation. 

The agenda for the public meeting 

will be made available on the Internet 

at http://www.fda.gov/Cosmetics/ 

InternationalActivities/ 

ConferencesMeetingsWorkshops/

InternationalCooperationon

CosmeticsRegulationsICCR/default.htm. 

Dated: March 6, 2012. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2012–5744 Filed 3–8–12; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Ancillary Studies 

for ISC Consortium. 

Date: March 29, 2012. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Maria E. Davila-Bloom, 

Ph.D., Scientific Review Officer, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 758, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 


srobinson on DSK4SPTVN1PROD with NOTICES